Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas.
Despite recent advances in the field, treatment options for metastatic soft tissue sarcoma patients are limited. Eribulin, an antimitotic derived from the natural marine sponge product halichondrin B, is currently approved for the treatment of metastatic breast cancer. Following the promising activity of eribulin in sarcoma in a Phase II trial, the drug was recently compared to dacarbazine in pretreated advanced leiomyosarcoma (LMS) and liposarcoma (LPS) patients in a Phase III trial. Eribulin was associated with a significant 2-month improvement in median overall survival compared to dacarbazine (13.5 vs. 11.5 months, heart rate: 0.768) despite no documented significant difference in progression-free survival. In a subgroup analysis, the survival advantage associated with eribulin was evident in the LPS subgroup but not in the LMS subgroup. Following these encouraging results, the Food and Drug Administration has approved eribulin for the treatment of advanced LPS for patients who received prior anthracycline chemotherapy. In this short review, we will evaluate the evidence for eribulin in soft tissue sarcoma, highlight its mechanisms of action, and summarize the results of the major preclinical and clinical studies with a particular focus on the results of the Phase III trial.
Sarcoma Unit, Maisonneuve-Rosemont Hospital, Montreal, H1T 2M4, Canada.
Jonathan
J
Noujaim
Sarcoma Unit, The Institute of Cancer Research, Royal Marsden Hospital, London, SW3 6JJ, United Kingdom.
Salma
S
Alam
Sarcoma Unit, The Institute of Cancer Research, Royal Marsden Hospital, London, SW3 6JJ, United Kingdom.
Khin
K
Thway
Sarcoma Unit, The Institute of Cancer Research, Royal Marsden Hospital, London, SW3 6JJ, United Kingdom.
Robin Lewis
RL
Jones
Efficacy; eribulin; leiomyosarcoma; liposarcoma; safety
J Clin Oncol. 2014 Oct 10;32(29):3299-306
25185097
Lancet. 2016 Apr 16;387(10028):1629-37
26874885
Int J Surg Pathol. 2016 Feb;24(1):5-15
26399578
Cancer Res. 2004 Aug 15;64(16):5760-6
15313917
Cancer. 2011 Mar 1;117(5):1049-54
20945333
Lancet. 2012 May 19;379(9829):1879-86
22595799
Clin Cancer Res. 2009 Jun 15;15(12 ):4213-9
19509146
Lancet. 2011 Mar 12;377(9769):914-23
21376385
Invest New Drugs. 2012 Oct;30(5):1926-33
21887501
Breast Cancer Res Treat. 2013 Jan;137(1):187-93
23143283
Mol Cancer Ther. 2005 Jul;4(7):1086-95
16020666
Lancet Oncol. 2011 Oct;12 (11):1045-52
21937277
J Clin Oncol. 2016 Mar 10;34(8):786-93
26371143
Br J Cancer. 2001 Apr 20;84(8):1070-5
11308256
Br J Cancer. 2014 Mar 18;110(6):1497-505
24569463
Vasc Cell. 2014 Mar 01;6(1):3
24581301
Clin Cancer Res. 2009 Jun 15;15(12 ):4207-12
19509177
Cancer Sci. 2014 Oct;105(10 ):1334-42
25060424
Clin Cancer Res. 2015 Jun 1;21(11):2445-52
25838395
J Clin Oncol. 2009 Jun 20;27(18):2954-61
19349550
Lancet Oncol. 2014 Apr;15(4):415-23
24618336
Mar Drugs. 2015 Aug 07;13(8):5016-58
26262627
Cancer Res. 2005 Jul 1;65(13):5881-9
15994966
Eur J Nucl Med Mol Imaging. 2003 May;30(5):695-704
12632200
Cancer Res. 2001 Feb 1;61(3):1013-21
11221827
Oncologist. 2012;17(9):1213-20
22907974